MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck

This study has been terminated.
(No subjects enrolled and PI went to another facility)
Sponsor:
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00427102
First received: January 24, 2007
Last updated: November 13, 2012
Last verified: November 2012
  Purpose

Rationale for Study

Oral mucositis is a major complication arising from contemporary chemoradiation treatment of patients with head and neck cancer.

No effective therapy exists to prevent this complication in this population. MRX-1024 is an investigational agent that has demonstrated in in vitro and in vivo experiments to have the potential to exert a protective effect in normal mucosa cells, without interfering with the intended antitumor effect of radiation.

A pilot Phase 1 study of MRX-1024 was conducted in India in patients with head and neck cancer receiving radiation alone or radiation in combination with cisplatin or carboplatin. MRX 1024 doses of 100 mgkg given orally twice a day, five days a week during radiation treatment cycles, were well tolerated and appeared to exert a protective effect against the development of severe mucositis.

Twice daily doses of MRX 1024 impose a certain level of inconvenience to the patient, to their clinic companion, and to the general work flow within radiation oncology clinics.

This study is designed to study the safety and pharmacokinetics of both single daily dose and twice daily dose regimens of oral MRX 1024 given in conjunction with daily radiation fractions and intermittent high-dose cisplatin to patients with high-risk for recurrence head and neck cancer following surgical resection. The study will also document the incidence and severity of oral mucositis that occurs following such therapy. The results will be instrumental in determining the regimen of MRX 1024 to use in subsequent definitive clinical trials.


Condition Intervention Phase
Squamous Cell Carcinoma
Head and Neck Cancer
Resected Head and Neck Cancer
Mucositis
Drug: Oral MRX-1024
Procedure: Standard Fractionation Radiation Therapy
Drug: High-Dose Cisplatin Chemotherapy
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection

Resource links provided by NLM:


Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • safe recommended doses and dose regimen for oral MRX-1024 with concurrent chemoradiation.
  • Identify toxicity profile of oral MRX-1024.
  • Determine pharmacokinetic parameters of oral MRX-1024.

Secondary Outcome Measures:
  • Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.

Study Start Date: January 2007
Study Completion Date: July 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-proved squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx;
  • Status-post surgical resection of primary disease and meeting criteria for post-operative radiotherapy and chemotherapy by evidence of histologic extracapsular nodal extension, or histologic involvement of >2 regional lymph nodes, or mucosal margin of resection with invasive cancer (limited to microscopic detection only);
  • Able to begin protocol treatment within 8 weeks of first tumor-related surgery;
  • Age >18 years. Because no dosing or adverse event data are currently available on the use of MRX-1024 in combination with radiotherapy and cisplatin or carboplatin, in patients less than 18 years of age, children are excluded from this study, but will be eligible for future pediatric Phase 1 combination studies in appropriate indications when sufficient safety and efficacy data in adults are available.
  • Karnofsky Performance Status of >70 (Appendix I);
  • Normal organ and marrow function as defined herein, determined by laboratory values obtained within seven days prior to receiving the first dose of protocol treatment:

    • Serum creatinine within institutional limits of normal
    • Creatinine clearance >50
    • Total bilirubin within institutional limits of normal
    • AST(SGOT) and ALT(SGPT) <2.5 times the upper limit of normal for the institution
    • White blood cell count >3500 per cubic millimeter
    • Absolute neutrophil count >1500 per cubic millimeter
    • Platelet count >100,000 per cubic millimeter
  • Ability to understand and the willingness to sign an informed consent document in accordance with institutional guidelines.

Exclusion Criteria:

  • Gross (visible or palpable) disease left after surgical resection;
  • Prior chemotherapy or radiation therapy to the head and neck region;
  • Primary site of the lip, nasopharynx or paranasal sinuses;
  • Distant metastases;
  • Known malabsorption syndrome;
  • Pregnancy or breast-feeding. The effects of MRX-1024 on the developing human fetus are unknown at this time. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) for the duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately;
  • Gastrointestinal tract disease or deformity resulting in an inability to take oral or enteral medication or nutrition;
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, untreated or new cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements;
  • History of taking any investigational medication within 4 weeks prior to receiving the first dose of protocol treatment.
  • Prior malignancy within the previous 5 years, excluding non-melanoma skin cancer and cervical cancer treated with local therapy.
  • Known allergy or sensitivity to polysorbate 80 (Tween).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00427102

Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Investigators
Principal Investigator: Gopal Bajaj, M.D. Johns Hopkins University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00427102     History of Changes
Other Study ID Numbers: J-0657, 06-01
Study First Received: January 24, 2007
Last Updated: November 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
Oral MRX-1024
High-Dose Cisplatin Chemotherapy
Standard Radiation Therapy

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Mucositis
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Cisplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014